Latest Pharmaceutical companies Stories

SCOLR Pharma Announces Issuance of European Patent for CDT® Ibuprofen

2012-07-11 02:26:08

BELLEVUE, Wash., July 11, 2012 /PRNewswire/ -- SCOLR Pharma, Inc. (PINK: SCLR) today announced that the European Patent Office has issued a patent covering SCOLR's oral modified release ibuprofen formulation, which is based on SCOLR's CDT® Controlled Delivery Technology platform. European patent number 1,793,809 covers SCOLR's approach for optimizing the release profile of ibuprofen, in order to achieve particular blood level concentrations of this active ingredient for a...

Tris Pharma Expands Manufacturing Capacity and Strengthens Supply Chain to Support New and Pending Approvals

2012-07-11 02:25:23

MONMOUTH JUNCTION, N.J., July 11, 2012 /PRNewswire/ -- Tris Pharma, a specialty pharmaceutical company with fully integrated commercial manufacturing and drug development operations, announced today that in order to meet demand for its products (approved and near term) the company has fortified its supply chain, increased manufacturing capacity and strengthened its management team. During the past two months, Tris has been fortunate to receive five new ANDA approvals from the...

Shionogi-ViiV Healthcare announces positive initial data from phase III study of dolutegravir-based regimen vs Atripla in HIV

2012-07-10 22:20:59

LONDON, July 11, 2012 /PRNewswire/ -- Shionogi-ViiV Healthcare LLC today announced that initial results have been received from the Phase III SINGLE (ING114467) study of the investigational integrase inhibitor dolutegravir in treatment-naive adults with HIV-1. The study demonstrated superiority of the dolutegravir-based regimen compared to the single tablet regimen Atripla®. At 48 weeks, 88% of study participants on the dolutegravir regimen were virologically suppressed (<50...

Mylan Applauds Signing of Landmark "Food and Drug Administration Safety and Innovation Act"

2012-07-09 14:23:10

PITTSBURGH, July 9, 2012 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today applauded President Obama's signing of the "Food and Drug Administration Safety and Innovation Act," landmark legislation that will significantly enhance the safety and security of the U.S. drug supply chain, level the playing field to hold all drug manufacturers to FDA's inspection standards and improve timely access to high quality, affordable generic drugs. Mylan CEO Heather Bresch commented, "Mylan has...

Anthera Pharmaceuticals to Present at the 7th Annual JMP Securities Healthcare Conference

2012-07-09 10:23:58

HAYWARD, Calif., July 9, 2012 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation and autoimmune disorders, today announced that Paul F. Truex, Anthera's President and Chief Executive Officer, will present the company's corporate overview on Friday, July 13, 2012, at 1:30 pm Eastern Time (10:30 am Pacific Time) during the 7th Annual JMP Securities Healthcare Conference at the...

Pappas Ventures Names Pat Gage to Scientific Advisory Board

2012-07-09 06:28:38

RESEARCH TRIANGLE PARK, N.C., July 9, 2012 /PRNewswire/ -- Pappas Ventures today announced the appointment of L. Patrick (Pat) Gage, PhD to the company's Scientific Advisory Board (SAB). Dr. Gage has extensive experience in the biotech and pharmaceutical industry, including previously-held senior positions at Hoffmann-La Roche, Genetics Institute and Wyeth (now Pfizer). Throughout his career, he oversaw the development of more than a dozen marketed biologics and vaccines, as...

infirst HEALTHCARE Established to Launch Novel Consumer Medicines

2012-07-08 22:21:13

LONDON, July 9, 2012 /PRNewswire/ -- Cocoa-flavoured cough medicine will be first product to market A consumer healthcare company, infirst HEALTHCARE, has today been established to launch and commercialise new, fast-to-market consumer medicines which bring a novel approach to a market where there has been little new innovation in decades. The new medicines utilize infirst's intellectual property to improve safe and well-established drugs and the first...

PDS Biotechnology Corporation Signs Worldwide Licensing Agreement with Merck KGaA for Versamune(TM)

2012-07-08 18:21:27

LAWRENCEBURG, Ind., July 9, 2012 /PRNewswire/ -- PDS Biotechnology Corporation announced today that they have entered into an exclusive worldwide licensing agreement with Merck KGaA, Darmstadt, Germany, for use of PDS Biotechnology's novel Versamune(TM) nanotechnology platform in two of Merck's investigational antigen-specific cancer immunotherapies currently in pre-clinical development. Merck obtains the rights to utilize the technology with two investigational antigen-specific...

Bayer Initiates Phase II/III Trial of New Recombinant Factor VIII Compound for Treatment of Hemophilia A

2012-07-07 22:20:15

WAYNE, N.J., July 8, 2012 /PRNewswire/ -- Bayer HealthCare today announced the company has started to enroll patients in an international Phase II/III trial to evaluate its investigational compound BAY94-9027 for the treatment of hemophilia A. The PROTECT VIII (PROphylaxis in hemophilia A patienTs via directly pEgylated long-aCTing rFVIII) trial is designed to investigate whether BAY94-9027, a recombinant human factor VIII (rFVIII), can prolong the duration of protection from...

Aoxing Pharmaceutical Company Announces Management Change

2012-07-06 02:22:39

JERSEY CITY, N.J., July 6, 2012 /PRNewswire/ -- Aoxing Pharmaceutical Company, Inc. (NYSEAMEX: AXN), a specialty pharmaceutical company specializing in research, development, manufacturing and distribution of a range of narcotics and pain-management products, today announced that Mr. Bob Yunjun Ai has resigned as Chief Financial Officer of the Company to pursue other business interests, effective as of July 1, 2012. The Company expresses its appreciation for Mr. Ai's significant...